EMERALD-3研究的重磅报告将展示英飞凡联合英卓凡用于早期肝癌治疗的获益

来自SERENA-6、DESTINY-Breast09和TROPION-Breast02的III期临床研究数据覆盖转移性乳腺癌的三种主要亚型

CARES研究三期结果显示抗淀粉样原纤维单克隆抗体anselamimab对于κappa型AL轻链淀粉样变性患者临床获益显著

上海2026年5月23日 -- 在2026年5月29日-6月2日召开的美国临床肿瘤学会（ASCO）年会上，阿斯利康将凭借多样化且行业领先的产品组合和研发管线，公布多项最新研究数据，进一步践行让癌症不再成为致死主因和改善罕见病患者治疗结局的宏伟愿景。

会上将公布超过85个摘要，其中涵盖10款已获批药物和13款潜在新药、25项口头报告。亮点包括：

EMERALD-3：评估了度伐利尤单抗与曲麦利尤单抗，联合或不联合仑伐替尼和经动脉化疗栓塞术（TACE），用于治疗适于栓塞的不可切除肝细胞癌（HCC）患者的III期临床研究（口头摘要#LBA4000）。
CARES：来自瑞颂制药（阿斯利康罕见病业务）潜在的首创抗淀粉样原纤维单克隆抗体anselamimab 的 III 期临床研究：用于治疗新诊断轻链型淀粉样变性患者，并将公布kappa或lambda轻链型淀粉样变患者的亚组分析结果（口头摘要#7501）。
SERENA-6：评估了Camizestrant 联合广泛获批的细胞周期蛋白依赖性激酶（CDK）4/6抑制剂，用于一线治疗激素受体（HR）阳性、人表皮生长因子受体2（HER2）阴性且肿瘤出现ESR1突变的晚期乳腺癌患者的三期试验——第二次无进展生存期（PFS2）最终结果，循环肿瘤 DNA（ctDNA）清除数据及其与长期疗效结局的相关性分析（口头摘要 #LBA1007）。
BLUESTAR：评估了在I/IIa期BLUESTAR临床试验中，靶向B7-H4的新型抗体偶联药物（ADC）Puxitatug samrotecan（Puxi-Sam）用于治疗已接受标准治疗的复发性或转移性B7-H4阳性子宫内膜癌和卵巢癌患者的安全性和有效性更新结果。（快速口头摘要#5515）。Puxi-Sam近日已被美国食品药品监督管理局（FDA）授予"突破性疗法"认定。
PRIMAVERA：评估了蛋白质精氨酸甲基转移酶5(PRMT5)抑制剂AZD3470单药用于治疗复发/难治性经典型霍奇金淋巴瘤的首次人体试验PRIMAVERA I期临床研究的安全性和初步疗效（口头摘要 #7003）。
NT-175 I期初步结果：针对TP53 R175H突变的不可切除、晚期及/或转移性胰腺腺癌等实体肿瘤的T细胞受体疗法（口头摘要#2506）。
TROPION-Breast02：评估了TROPION-Breast02 III期临床试验中，德达博妥单抗用于无法接受PD-1/PD-L1抑制剂治疗的局部复发不可手术或转移性三阴性乳腺癌（TNBC）患者一线治疗的额外疗效终点（口头摘要 #1002）。
DESTINY-Breast09：评估了在DESTINY-Breast09 III期临床试验中，德曲妥珠单抗联合帕妥珠单抗用于HER2阳性转移性乳腺癌患者的一线治疗，基于完全缓解、部分缓解或疾病稳定/进展对治疗持续时间和临床结局进行的探索性分析（快速口头摘要#1021）。
POTOMAC：评估了在III期POTOMAC临床试验中，度伐利尤单抗联合卡介苗（BCG）诱导和维持治疗高危非肌层浸润性膀胱癌患者的五年总生存期与患者报告结果（快速口头摘要#4624）。

阿斯利康全球执行副总裁、肿瘤研发负责人高书璨（Susan Galbraith）表示："本次ASCO大会上公布的创新药物和下一代疗法数据，进一步推动了我们的战略——通过新型联合疗法应用于疾病早期阶段，并不断拓展创新疗法来改变肿瘤患者治疗结局。德曲妥珠单抗、德达博妥单抗和camizestrant的重磅数据证实了它们在乳腺癌领域变革性的潜力。我们也很高兴分享T细胞受体疗法NT-175和PRMT5抑制剂AZD3470的首次临床数据，以及公司自主研发的最领先的抗体偶联药物之一Puxi-Sam的最新数据，Puxi-Sam近日已被美国食品药品监督管理局（FDA）授予'突破性疗法'认定。这些数据充分彰显了肿瘤研发管线的强大实力与深厚底蕴。"

阿斯利康全球执行副总裁，肿瘤业务负责人Dave Fredrickson表示："EMERALD-3的研究数据证明，度伐利尤单抗联合曲麦利尤单抗用于早期肝癌的治疗，是我们将免疫疗法迁入癌症早期阶段治疗策略的成功例证，进而改善患者治疗结局。仅是在过去六个月中，我们的五款肿瘤药物获批了超过十个不同的适应症，日益丰富的产品组合正在惠及更多患者，这充分彰显了阿斯利康在肿瘤领域的创新质量与业务实力。"

瑞颂制药临床开发、注册及患者安全负责人Gianluca Pirozzi表示："CARES III期临床研究结果突显了anselimamab作为首创抗淀粉样原纤维单克隆抗体，在治疗kppa轻链型淀粉样变性患者中的潜力。其创新机制旨在靶向清除受累器官中的淀粉样蛋白沉积，有望延长患者生存期并减少因心血管事件引发的住院频次。"

阿斯利康与第一三共联合开发和商业化德曲妥珠单抗和德达博妥单抗。

阿斯利康在2026 ASCO年会公布的重磅数据^[^1]

主要作者 Lead Author	摘要标题 Abstract Title	详情Presentation details (CDT)
抗体偶联药物 Antibody drug conjugates
Loi, S	Trastuzumab deruxtecan (T-DXd) + durvalumab (D) in patients (pts) with previously untreated HER2+ unresectable/metastatic breast cancer (mBC): Final analysis from DESTINY- Breast07.	Abstract #1012 Clinical Science Symposium 31 May 2026 09:18
Cescon, DW	First-line datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients with locally recurrent inoperable or metastatic triple- negative breast cancer (TNBC) for who immunotherapy was not an option: Additional efficacy endpoints from the TROPION-Breast02 study.	Abstract #1002 Oral Abstract Session 2 June 2026 10:09
Mileshkin, LR	Updated safety and efficacy of puxitatug samrotecan (Puxi-Sam, AZD8205) in patients (pts) with endometrial cancer (EC) or ovarian cancer (OC): Phase 1/2a BLUESTAR study.	Abstract #5515 Rapid Oral Abstract Session 30 May 2026 09:00
Park, YH	A DESTINY-Breast09 analysis of treatment duration and clinical outcomes by best response to trastuzumab deruxtecan (T-DXd) + pertuzumab (P).	Abstract #1021 Rapid Oral Abstract Session 31 May 2026 12:42
Untch, M	Secondary safety analysis of trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in DESTINY-Breast05: Clinical and demographic risk factors of interstitial lung disease (ILD) and radiation pneumonitis (RP).	Abstract #516 Rapid Oral Abstract Session 1 June 2026 10:57
Shitara, K	Sonesitatug vedotin (Sone-Ve) monotherapy in patients (pts) with claudin 18.2–positive (CLDN18.2+) advanced or metastatic gastric or gastroesophageal junction (GEJ) cancers: Data from CLARITY- PanTumor01.	Abstract #4023 Poster Session 30 May 2026 09:00
Janjigian, Y	First-line (1L) trastuzumab deruxtecan (T-DXd)–based regimens in advanced HER2-expressing gastric cancer (GC), gastroesophageal junction adenocarcinoma (GEJA), or esophageal adenocarcinoma (EA): Safety results from DESTINY-Gastric03 (DG-03) Part 2 arms D and F, and Part 4.	Abstract #4022 Poster Session 30 May 2026 09:00
Zhang, Y	Trastuzumab deruxtecan (T-DXd) for pretreated patients in China with HER2 IHC 3+ solid tumors: DESTINY- PanTumor03 Part 1 primary analysis.	Abstract #3026 Poster Session 30 May 2026 13:30
免疫肿瘤学 Immuno-oncology
Abou-Alfa, GK	Efficacy and safety results from EMERALD-3: A phase 3, randomized study of tremelimumab plus durvalumab with or without lenvatinib combined with transarterial chemoembolization (TACE) in participants (pts) with unresectable embolization-eligible hepatocellular carcinoma (eeHCC).	Abstract #LBA4000 Oral Abstract Session 1 June 2026 09:45
Skoulidis, F	Tremelimumab (T) + durvalumab (D) + chemotherapy (CT) vs pembrolizumab (P) + CT in 1L non-squamous (NSQ) metastatic NSCLC (mNSCLC) with STK11, KEAP1, and/or KRAS mutations (mut): Interim analysis (IA) of the phase 2b TRITON study.	Abstract #8515 Rapid Oral Abstract Session 30 May 2026 13:45
Heymach, JV	Impact of neoadjuvant durvalumab (D) on tumor microenvironment (TME) features and their association with event-free survival (EFS) in patients with resectable NSCLC (R-NSCLC) from the phase 3 AEGEAN trial.	Abstract #8015 Rapid Oral Abstract Session 31 May 2026 17:30
De Santis, M	Durvalumab (D) in combination with BCG induction and maintenance (I + M) therapy for BCG-naive, high-risk non–muscle-invasive bladder cancer (NMIBC): 5-year overall survival (OS) analysis and patient-reported outcomes (PROs) from POTOMAC.	Abstract #4624 Rapid Oral Abstract Session 1 June 2026 08:12
免疫肿瘤学与双特异性抗体 IO Bispecifics
O'Sullivan, CC	Neoadjuvant rilvegostomig (R) + trastuzumab deruxtecan (T-DXd) in high-risk HER2-negative breast cancer: Results from the I-SPY 2.2 trial.	Abstract #LBA514 Rapid Oral Abstract Session 1 June 2026 10:45
Zhou, J	First-line rilvegostomig (R) + chemotherapy (CTx) in advanced biliary tract cancer (BTC): Updated analysis of GEMINI-Hepatobiliary substudy 2 cohort A.	Abstract #88 Poster Session 30 May 2026 09:00
Guo, Y	Volrustomig monotherapy for recurrent/metastatic HNSCC: Substudy 2 of the eVOLVE-02 phase 2 study.	Abstract #482 Poster Session 30 May 2026 13:30
肿瘤驱动因素和耐药性 Tumour drivers and resistance
Wang, Z	Osimertinib with/without chemotherapy in patients with persistent ctDNA EGFR mutant (EGFRm) NSCLC at 3 weeks after 1L osimertinib: A randomized phase II study (FLAME study).	Abstract #LBA101 Clinical Science Symposium 30 May 2026 08:40
Bidard, FC	First-line (1L) camizestrant (CAMI) for emergent ESR1 mutations (ESR1m) in advanced breast cancer (ABC): Final progression-free survival 2 (PFS2) from the phase III SERENA-6 trial.	Abstract #LBA1007 Oral Abstract Session 2 June 2026 11:57
Peng, Z	A phase 2 pivotal study of savolitinib in patients with MET-amplified gastric cancer or gastroesophageal junction adenocarcinomas.	Abstract #4011 Rapid Oral Abstract Session 1 June 2026 13:27
细胞疗法 Cell Therapy
Surana, R	Initial phase 1 study results of NT-175 engineered T-cell therapy in TP53 R175H–mutated unresectable advanced solid tumors.	Abstract #2506 Oral Abstract Session 31 May 2026 10:00
表观遗传学 Epigenetics
Derenzini, E	A phase 1 study of the PRMT5 inhibitor AZD3470 in patients with relapsed/refractory classic Hodgkin lymphoma (PRIMAVERA).	Abstract #7003 Oral Abstract Session 30 May 2026 16:00
罕见病 Rare Disease
Wechalekar, AD	Phase 3 randomized trial to evaluate the impact of anselamimab on all- cause mortality in κ light chain amyloidosis.	Abstract #7501 Oral Abstract Session 29 May 2026 14:57
Chen, AP	Final analysis of KOMET (NCT04924608), a phase 3 study of selumetinib in adults with NF1-PN.	Abstract #3110 Poster Session 30 May 2026 13:30

[1] 阿斯利康在2026年ASCO大会将公布超过85个摘要，涵盖已上市药物和研发管线中的分子药物